antiprotozoal agents

Summary

Summary: Substances that are destructive to protozoans.

Top Publications

  1. ncbi Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
    Francois Chappuis
    Travel and Migration Medicine Unit, Geneva University Hospitals, 24 Rue Micheli du Crest, CH 1211 Geneva 14, Switzerland
    Nat Rev Microbiol 5:873-82. 2007
  2. ncbi Leishmaniasis: current situation and new perspectives
    P Desjeux
    Department of Control, Prevention and Elimination CDS CPE, Cluster of Communicable Diseases, World Health Organization WHO, Avenue Appia, 1211 Geneva 27, Switzerland
    Comp Immunol Microbiol Infect Dis 27:305-18. 2004
  3. ncbi Advances in leishmaniasis
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, USA
    Lancet 366:1561-77. 2005
  4. pmc Drug resistance in leishmaniasis
    Simon L Croft
    Drugs for Neglected Diseases Initiative, 1 place Saint Gervais, CH 1201 Geneva, Switzerland
    Clin Microbiol Rev 19:111-26. 2006
  5. ncbi Leishmaniasis and poverty
    Jorge Alvar
    Communicable Diseases, Neglected Tropical Diseases Control, World Health Organization, 20 Ave Appia, CH 1211 Geneva 27, Switzerland
    Trends Parasitol 22:552-7. 2006
  6. ncbi Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches
    Julio A Urbina
    Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela
    Acta Trop 115:55-68. 2010
  7. ncbi Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis
    Hiro Goto
    Laboratório de Soroepidemiologia do Instituto de Medicina Tropical da Universidade de São Paulo, Avenida Dr Eneas de Carvalho Aguiar, prédio II, Sao Paulo, SP, Brazil
    Expert Rev Anti Infect Ther 8:419-33. 2010
  8. ncbi Leishmaniasis
    B L Herwaldt
    Centers for Disease Control and Prevention, Division of Parasitic Diseases, Atlanta, GA 30341 3724, USA
    Lancet 354:1191-9. 1999
  9. ncbi Development of novel drugs for human African trypanosomiasis
    Reto Brun
    Department Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, and, University of Basel, CH 4002 Basel, Switzerland
    Future Microbiol 6:677-91. 2011
  10. ncbi Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs
    Simon L Croft
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Trends Parasitol 19:502-8. 2003

Detail Information

Publications283 found, 100 shown here

  1. ncbi Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
    Francois Chappuis
    Travel and Migration Medicine Unit, Geneva University Hospitals, 24 Rue Micheli du Crest, CH 1211 Geneva 14, Switzerland
    Nat Rev Microbiol 5:873-82. 2007
    ..New diagnostic tools and new treatment strategies will only have an impact if they are made widely available to patients...
  2. ncbi Leishmaniasis: current situation and new perspectives
    P Desjeux
    Department of Control, Prevention and Elimination CDS CPE, Cluster of Communicable Diseases, World Health Organization WHO, Avenue Appia, 1211 Geneva 27, Switzerland
    Comp Immunol Microbiol Infect Dis 27:305-18. 2004
    ..The newly available control tools should allow a scaling up of control activities in priority areas. In anthroponotic foci, the feasibility of getting a strong impact on mortality, morbidity and transmission, is high...
  3. ncbi Advances in leishmaniasis
    Henry W Murray
    Department of Medicine, Weill Medical College of Cornell University, New York, USA
    Lancet 366:1561-77. 2005
    ..Current obstacles to realistic prevention and proper management include inadequate vector (sandfly) control, no vaccine, and insufficient access to or impetus for developing affordable new drugs...
  4. pmc Drug resistance in leishmaniasis
    Simon L Croft
    Drugs for Neglected Diseases Initiative, 1 place Saint Gervais, CH 1201 Geneva, Switzerland
    Clin Microbiol Rev 19:111-26. 2006
    ....
  5. ncbi Leishmaniasis and poverty
    Jorge Alvar
    Communicable Diseases, Neglected Tropical Diseases Control, World Health Organization, 20 Ave Appia, CH 1211 Geneva 27, Switzerland
    Trends Parasitol 22:552-7. 2006
    ..Public investment in treatment and control would decrease the leishmaniasis disease burden and help to alleviate poverty...
  6. ncbi Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches
    Julio A Urbina
    Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela
    Acta Trop 115:55-68. 2010
    ....
  7. ncbi Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis
    Hiro Goto
    Laboratório de Soroepidemiologia do Instituto de Medicina Tropical da Universidade de São Paulo, Avenida Dr Eneas de Carvalho Aguiar, prédio II, Sao Paulo, SP, Brazil
    Expert Rev Anti Infect Ther 8:419-33. 2010
    ..In addition to a review of the drugs currently utilized, we describe differences in their effectiveness in Old and New World leishmaniasis. HIV/Leishmania coinfection is also presented in the context of diagnosis and treatment...
  8. ncbi Leishmaniasis
    B L Herwaldt
    Centers for Disease Control and Prevention, Division of Parasitic Diseases, Atlanta, GA 30341 3724, USA
    Lancet 354:1191-9. 1999
    ....
  9. ncbi Development of novel drugs for human African trypanosomiasis
    Reto Brun
    Department Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, and, University of Basel, CH 4002 Basel, Switzerland
    Future Microbiol 6:677-91. 2011
    ..With other screening programs yielding hits, the pipeline for new HAT drugs might finally begin to fill...
  10. ncbi Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs
    Simon L Croft
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Trends Parasitol 19:502-8. 2003
  11. ncbi Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda
    Philippe J Guerin
    Norwegian Institute of Public Health, Norway
    Lancet Infect Dis 2:494-501. 2002
    ..This article reviews the current situation and perspectives for diagnosis, treatment, and control of visceral leishmaniasis, and lists some priorities for research and development...
  12. ncbi Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence
    Koert Ritmeijer
    Public Health Department, Medecins Sans Frontieres, Amsterdam, The Netherlands
    Clin Infect Dis 53:e152-8. 2011
    ....
  13. pmc Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness
    Els Torreele
    Drugs for Neglected Diseases Initiative DNDi, Geneva, Switzerland
    PLoS Negl Trop Dis 4:e923. 2010
    ..To complete the preclinical development and meet the regulatory requirements before initiating human trials, the anti-parasitic properties and the pharmacokinetic, metabolic and toxicological profile of fexinidazole have been assessed...
  14. ncbi Combination therapy for visceral leishmaniasis
    Johan van Griensven
    Department of Clinical Sciences, Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium
    Lancet Infect Dis 10:184-94. 2010
    ..Whether combination therapy could indeed help delay resistance, and how this is best achieved, will only be known in the long term...
  15. ncbi Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use
    Shyam Sundar
    Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
    Clin Infect Dis 55:543-50. 2012
    ..Its unrestricted use has raised concern about its continued effectiveness. This study evaluates the efficacy and safety of miltefosine for the treatment of VL after a decade of use in India...
  16. pmc Antileishmanial activity of a linalool-rich essential oil from Croton cajucara
    Maria do Socorro S do Socorro S Rosa
    Instituto de Microbiologia Prof Paulo de Goes, Centro de Ciencias da Saude, Universidade Federal do Rio de Janeiro, Rio de Janeiro, R J, 219491 590, Brazil
    Antimicrob Agents Chemother 47:1895-901. 2003
    ..3 ng/ml for promastigotes and 8.7 ng/ml for amastigotes) which inhibited the growth of L. amazonensis promastigotes at very low concentrations (MIC, 85.0 pg/ml) and which presented no cytotoxic effects against mammalian cells...
  17. pmc Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial
    Ahmed Musa
    Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    PLoS Negl Trop Dis 6:e1674. 2012
    ..Alternative treatments for visceral leishmaniasis (VL) are required in East Africa. Paromomycin sulphate (PM) has been shown to be efficacious for VL treatment in India...
  18. ncbi Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia
    Zewdu Hurissa
    University of Gondar, College of Medicine and Health Sciences, Gondar, Ethiopia
    Trop Med Int Health 15:848-55. 2010
    ..To describe the clinical presentation of patients with visceral leishmaniasis (VL) with and without human immunodeficiency virus (HIV) co-infection and factors associated with poor outcome in northwest Ethiopia...
  19. pmc Drug susceptibility testing of anaerobic protozoa
    J A Upcroft
    Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia
    Antimicrob Agents Chemother 45:1810-4. 2001
    ..duodenalis (3 days) ranged from 6.3 microM for metronidazole-sensitive isolates to 50 microM for laboratory metronidazole-resistant lines. This technique should encourage more extensive monitoring of drug resistance in these organisms...
  20. ncbi An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans
    Sophie Goyard
    Department of Molecular Microbiology, Washington University Medical School, Campus Box 8230, 660 S Euclid Ave, St Louis, MO 63110, USA
    Mol Biochem Parasitol 130:31-42. 2003
    ..These and other data suggest that LdB axenic amastigotes will be generally useful as a differentiation model in studies of gene expression, virulence, glycoconjugate function and drug susceptibility in L. donovani...
  21. ncbi Drug resistance in Indian visceral leishmaniasis
    S Sundar
    Kala Azar Medical Research Centre, Banaras Hindu University, Varanasi, India
    Trop Med Int Health 6:849-54. 2001
    ..Lipid associated amphotericin B has an excellent safety and efficacy profile, but remains out of reach for most patients because of its high cost...
  22. ncbi Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis
    Jorge Arevalo
    Instituto de Medicina Tropical Alexander von Humboldt, Facultad de Ciencias, Universidad Peruana Cayetano Heredia, Lima, Peru, and Hôpitaux Universitaires de Genève, Department of Community Medicine, Switzerland
    J Infect Dis 195:1846-51. 2007
    ..There are, however, reports of the occurrence of treatment failure with these drugs. Few studies in Latin America have compared the response to SbV treatment in ATL caused by different Leishmania species...
  23. ncbi Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani
    R Lira
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 180:564-7. 1999
    ..No correlation with clinical response was found by use of extracellular promastigotes (ED50=48+/-22 vs. 52+/-29 microgram/mL). The emergence of antimony-resistant L. donovani strains appears to be a cause of treatment failures in India...
  24. pmc Post-kala-azar dermal leishmaniasis in Nepal: a retrospective cohort study (2000-2010)
    Surendra Uranw
    Department of Internal Medicine, BP Koirala Institute of Health Sciences, Ghopa, Dharan, Nepal
    PLoS Negl Trop Dis 5:e1433. 2011
    ..We estimated the risk and risk factors of PKDL in patients with past VL treatment in south-eastern Nepal...
  25. pmc Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani
    Bidyut Purkait
    Department of Molecular Biology, Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna, Bihar, India
    Antimicrob Agents Chemother 56:1031-41. 2012
    ..Thus, it can be concluded that altered membrane composition, ATP-binding cassette transporters, and an upregulated thiol metabolic pathway have a role in conferring amphotericin B resistance in clinical isolates of Leishmania donovani...
  26. pmc Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug
    Rani Pallavi
    Department of Biochemistry, Indian Institute of Science, Bangalore, Karnataka 560012, India
    J Biol Chem 285:37964-75. 2010
    ..evansi growth in a mouse model of trypanosomiasis. In all, our biochemical characterization, drug interaction, and animal studies supported Hsp90 as a drug target and its inhibitor as a potential drug against protozoan diseases...
  27. ncbi Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species
    R Palacios
    Centro Internacional de Entrenamiento e Investigaciones Medicas, Cali, Colombia
    Am J Trop Med Hyg 64:187-93. 2001
    ..Pathogenicity of infection and pharmacokinetics may affect the treatment response in children. New therapeutic alternatives should be evaluated in trials that include children and women...
  28. pmc Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes
    Caroline Paris
    UMR 8076 CNRS, Chimiothérapie Antiparasitaire, France
    Antimicrob Agents Chemother 48:852-9. 2004
    ..Identification of the death-signaling pathways activated in HePC-sensitive parasites appears to be essential for a better understanding of the molecular mechanisms of action and resistance in these parasites...
  29. ncbi Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India
    Swati Mandal
    School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110067, India
    J Antimicrob Chemother 65:496-507. 2010
    ..The present work investigates the role of AQP1 in monitoring antimonial resistance in Indian leishmaniasis...
  30. pmc Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates
    Susan Wyllie
    Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH Scotland, UK
    Mol Biochem Parasitol 173:162-4. 2010
    ..These data suggest that enhanced anti-oxidant defences may play a significant role in clinical resistance to antimonials...
  31. ncbi Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani
    Susan Wyllie
    Division of Biological Chemistry and Molecular Biology, Wellcome Trust Biocentre, School of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland
    J Biol Chem 279:39925-32. 2004
    ..These observations suggest ways in which current antimony therapies could be improved, overcoming the growing problem of antimony resistance...
  32. ncbi Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis
    J Alexander
    Department of Immunology, University of Strathclyde, Glasgow, GB
    Eur J Immunol 30:2935-43. 2000
    ..These results demonstrate that IL-4 has an important role in effective anti-leishmanial chemotherapy which seems to be related to modulation of IFN-gamma production...
  33. ncbi American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?
    Vanessa Yardley
    London School of Hygiene and Tropical Medicine, Department of Infectious and Tropical Diseases, London, United Kingdom
    J Infect Dis 194:1168-75. 2006
    ..We aimed to characterize the in vitro antimony susceptibility of clinical isolates of Peruvian patients with ATL who were treated with sodium stibogluconate and to correlate this in vitro phenotype with different treatment outcomes...
  34. ncbi Current scenario of drug development for leishmaniasis
    Simon L Croft
    Drugs for Neglected Diseases Initiative DNDi, Geneva, Switzerland
    Indian J Med Res 123:399-410. 2006
    ..The process for discovery and development of new antileishmanials would also benefit from improved models, for example, transfected parasites, and non invasive methods of measuring parasite load in rodent models of infection...
  35. pmc SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis
    Robert T Jacobs
    SCYNEXIS, Inc, Research Triangle Park, North Carolina, USA
    PLoS Negl Trop Dis 5:e1151. 2011
    ..We have discovered and optimized a novel class of small-molecule boron-containing compounds, benzoxaboroles, to identify SCYX-7158 as an effective, safe and orally active treatment for HAT...
  36. ncbi Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis
    Ricardo M Santa-Rita
    Dept de Ultra estrutura e Biologia Celular, Instituto Oswaldo Cruz, Fundacao Oswaldo Cruz, 21045 900, Rio de Janeiro RJ, Brazil
    J Antimicrob Chemother 54:704-10. 2004
    ..Analysis of the effect of edelfosine, ilmofosine and miltefosine on Leishmania amazonensis and of potential targets of these lysophospholipid analogues...
  37. ncbi Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs
    R Hadighi
    Department of Parasitology, Faculty of Medicine, Iran University of Medical Sciences, 14496, Tehran, Iran
    Parasitol Res 101:1319-22. 2007
    ..However, these resistant isolates were shown to be sensitive to miltefosine and paromomycin. The latter two drugs could thus be useful alternatives for the treatment of leishmaniasis in Iran even for SbV-resistant isolates...
  38. ncbi A review of natural products with antileishmanial activity
    L G Rocha
    Departamento de Microbiologia e Parasitologia, Universidade Federal do Rio Grande do Norte, 59000 000 Natal, RN, Brazil
    Phytomedicine 12:514-35. 2005
    ..It also includes 288 compounds isolated from higher plants and microorganisms, classified into appropriate chemical groups. Some aspects of recent antileishmanial-activity-directed research on natural products are discussed...
  39. pmc Theileria apicoplast as a target for chemotherapy
    Regina Lizundia
    Département Maladies Infectieuses, Laboratoire de Biologie Cellulaire Comparative des Apicomplexes, UMR 8104 CNRS U567 INSERM, Hôpital Cochin Bâtiment Gustave Roussy, Institut Cochin, Paris, France
    Antimicrob Agents Chemother 53:1213-7. 2009
    ..Putative inhibitors of these targets were screened, and we identified antiproliferative compounds that merit further characterization...
  40. ncbi Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial
    Shyam Sundar
    Kala azar Medical Research Center, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
    Lancet 377:477-86. 2011
    ..Improved treatment approaches are needed for visceral leishmaniasis. We assessed the efficacy and safety of three potential short-course combination treatments compared with the standard monotherapy in India...
  41. ncbi Sterol methenyl transferase inhibitors alter the ultrastructure and function of the Leishmania amazonensis mitochondrion leading to potent growth inhibition
    Juliany C F Rodrigues
    Laboratorio de Ultraestrutura Celular Hertha Meyer, Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, CCS Bloco G, Ilha do Fundao, 21949 900 Rio de Janeiro RJ, Brazil
    Protist 158:447-56. 2007
    ..The present study confirms these findings, showing that in Leishmania amazonensis the mitochondrial complex appears to be the first organelle affected after treatment with different SMTI...
  42. pmc Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites
    Ramtin Hadighi
    School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran
    PLoS Med 3:e162. 2006
    ..This study was designed to determine whether the clinical responses (healing, or non-healing) were correlated with the susceptibility of Leishmania parasites to Glucantime...
  43. ncbi Oral miltefosine for Indian visceral leishmaniasis
    Shyam Sundar
    Institutes of Medical Sciences, Banaras Hindu University, Varanasi, India
    N Engl J Med 347:1739-46. 2002
    ..We performed a clinical trial in India comparing miltefosine with the most effective standard treatment, amphotericin B...
  44. ncbi Liposomal amphotericin B for the treatment of visceral leishmaniasis
    Caryn Bern
    Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Clin Infect Dis 43:917-24. 2006
    ..The public health community should work to broaden access to preferential liposomal amphotericin B pricing by public sector VL treatment programs...
  45. ncbi Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis
    V Ramesh
    Department of Dermatology, Safdarjung Hospital Institute of Pathology ICMR, Safdarjung Hospital Campus, New Delhi 110029, India
    Br J Dermatol 165:411-4. 2011
    ..Unacceptable treatment regimens and increasing drug resistance blight control programmes. The success of oral miltefosine in VL prompted a clinical, histopathological and parasitological study of this drug in PKDL...
  46. pmc An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages
    Jair L Siqueira-Neto
    Center for Neglected Diseases Drug Discovery CND3, Institut Pasteur Korea, Seongnam si, Gyeonggi Do, South Korea
    PLoS Negl Trop Dis 6:e1671. 2012
    ..These data corroborate the idea that the intracellular amastigote form of the parasite is the most appropriate to be used in primary screening assay for Leishmania...
  47. ncbi Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda
    Y Mueller
    Medecins Sans Frontieres, Swiss Section, Rue de Lausanne 78, 1202 Geneva, Switzerland
    Ann Trop Med Parasitol 102:11-9. 2008
    ..2% (CI = 0.1%-4.4%) of the patients treated with Sb(V) (P>0.20). For the treatment of visceral leishmaniasis in Uganda, AmB therefore had a similar effectiveness and safety profile to that of meglumine antimoniate...
  48. pmc Dicationic phenyl-2,2'-bichalcophenes and analogues as antiprotozoal agents
    Mohamed A Ismail
    Department of Chemistry, Mansoura University, Egypt
    Bioorg Med Chem 19:978-84. 2011
    ..b. r.) and four gave IC₅₀values less than 7 nM against Plasmodium falciparum (P. f.). Only one of the compounds was as effective as reference compounds in the T. b. r. mouse model for the acute phase of African trypanosomiasis...
  49. pmc Clinical epidemiologic profile of a cohort of post-kala-azar dermal leishmaniasis patients in Bihar, India
    Vidya Nand Rabi Das
    Rajendra Memorial Research Institute of Medical Sciences ICMR, Agamkuan, Patna, Bihar, India
    Am J Trop Med Hyg 86:959-61. 2012
    ..59, P = 0.001). Because PKDL was observed during treatment with all currently used anti-leishmanial drugs, new drug regimens having high cure rates and potential to lower the PKDL incidence need to be investigated...
  50. pmc A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit
    Géraldine De Muylder
    Department of Pathology, Sandler Center for Drug Discovery, University of California San Francisco, San Francisco, California, United States of America
    PLoS Negl Trop Dis 5:e1253. 2011
    ..This compound affects intracellular but not axenic parasites, suggesting a host cell-dependent mechanism of action, opening new avenues for anti-leishmanial chemotherapy...
  51. pmc Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis
    Deuan C Jones
    Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK
    Biochem Pharmacol 80:1478-86. 2010
    ..Among the other potent, but less selective screening hits were compound classes with activity against protein kinases, topoisomerases, tubulin, as well as DNA and energy metabolism...
  52. ncbi Current approaches to discover marine antileishmanial natural products
    Andre G Tempone
    Department of Parasitology, Laboratory of Applied Toxinology on Anti Parasitic Drugs, Instituto Adolfo Lutz, Sao Paulo, SP, Brazil
    Planta Med 77:572-85. 2011
    ..Finally, we comprehensively review the marine natural products that are active against Leishmania spp., including their natural sources and bioactivity profile...
  53. ncbi Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells
    Rupkatha Mukhopadhyay
    Indian Institute of Chemical Biology, Council of Scientific and Industrial Research, Kolkata, India
    Int J Parasitol 41:1311-21. 2011
    ..The above results reinforce the notion that antimony resistant parasites have undergone a number of biochemical and biophysical changes as part of their adaptation to ensure their survival in the host...
  54. pmc Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds
    Jair L Siqueira-Neto
    Center for Neglected Diseases Drug Discovery CND3, Institut Pasteur Korea, Seongnam si, Gyeonggi Do, South Korea
    PLoS Negl Trop Dis 4:e675. 2010
    ..The HTS approach employed here resulted in the discovery of two new antileishmanial compounds, bringing promising candidates to the leishmaniasis drug discovery pipeline...
  55. pmc In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells
    Raquel Inocêncio da Luz
    Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Antwerp University, Antwerp, Belgium
    Antimicrob Agents Chemother 53:5197-203. 2009
    ..In conclusion, the proposed conditioning protocol further contributes toward a more standardized laboratory model for evaluation of the drug sensitivities of field isolates...
  56. pmc Expression of green fluorescent protein as a marker for effects of antileishmanial compounds in vitro
    S W Kamau
    Institute of Parasitology, , , Switzerland
    Antimicrob Agents Chemother 45:3654-6. 2001
    ..The GFP-based assay provided a reliable measure of drug-induced inhibitory effects on protein expression, resulting in a dynamic picture of the responses of leishmanial promastigotes to the compounds tested...
  57. pmc Miltefosine affects lipid metabolism in Leishmania donovani promastigotes
    M Rakotomanga
    Chimiothérapie Antiparasitaire, UMR 8076 CNRS, Faculte de Pharmacie, Universite Paris Sud XI, F 92290 Chatenay Malabry, France
    Antimicrob Agents Chemother 51:1425-30. 2007
    ....
  58. ncbi Antileishmanial activity and immune modulatory effects of tannins and related compounds on Leishmania parasitised RAW 264.7 cells
    Herbert Kolodziej
    Freie Universitat Berlin, Institute of Pharmacy, Pharmaceutical Biology, Konigin Luise Str 2 4, D 14195 Berlin, Germany
    Phytochemistry 66:2056-71. 2005
    ....
  59. pmc Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil
    Anette Chrusciak-Talhari
    Fundação de Medicina Tropical do Amazonas and Universidade Estadual do Amazonas, Manaus, AM, Brasil
    Am J Trop Med Hyg 84:255-60. 2011
    ..05) for miltefosine and antimonial, respectively. There were no differences in cure rates between age groups within the same treatment arms. Miltefosine was safe and relatively well tolerated and cure rate was higher than antimony...
  60. ncbi Single-dose liposomal amphotericin B for visceral leishmaniasis in India
    Shyam Sundar
    Kala azar Medical Research Center, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
    N Engl J Med 362:504-12. 2010
    ..We wanted to determine whether the efficacy of a single infusion of liposomal amphotericin B was inferior to conventional parenteral therapy, consisting of 15 alternate-day infusions of amphotericin B deoxycholate...
  61. ncbi Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome
    K Ritmeijer
    Medecins Sans Frontieres Holland, P O Box 10014, 1001 EA Amsterdam, The Netherlands
    Trans R Soc Trop Med Hyg 95:668-72. 2001
    ..3%). Only 43.5% of the HIV-positive patients were considered cured at 6-months follow-up vs 92.1% of the HIV-negative patients. HIV-positive patients relapsing with VL could become a reservoir of antimonial-resistant Leishmania donovani...
  62. ncbi Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy
    Harry P de Koning
    Institute of Biomedical and Life Sciences, Division of Infection and Immunity, Joseph Black Building, University of Glasgow, Glasgow G12 8QQ, UK
    FEMS Microbiol Rev 29:987-1020. 2005
    ..Recent studies are increasingly addressing the structure and substrate recognition mechanisms of these vital transport proteins...
  63. ncbi Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate
    G A Romero
    , , Brazil
    Am J Trop Med Hyg 65:456-65. 2001
    ..We concluded that Leishmania species constitute an important factor in predicting the outcome of cutaneous leishmaniasis treated with a pentavalent antimonial...
  64. ncbi Visceral leishmaniasis - current therapeutic modalities
    Shyam Sundar
    Kala azar Medical Research Center, Department of Medicine, Institute of Medical Sciences Banaras Hindu University, Varanasi, India
    Indian J Med Res 123:345-52. 2006
    ....
  65. ncbi Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models
    Anuradha Dube
    Division of Parasitology, Central Drug Research Institute, Post Box No 173, Lucknow 226 001, India
    Parasitol Res 96:216-23. 2005
    ..Two isolates were also transfected with green fluorescent protein (GFP) for the development of in vitro assay for studying antileishmanial activities of new and reference drugs in macrophages by flow cytometry...
  66. ncbi Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?
    Suman Rijal
    B P Koirala Institute of Health Sciences, Ghopa, Dharan, Nepal
    Microbes Infect 9:529-35. 2007
    ..Our results highlight the need to adjust the currently used Leishmania drug susceptibility assays if they are to be used for prognosis of in vivo SSG treatment outcome...
  67. pmc Kinetoplastids: related protozoan pathogens, different diseases
    Ken Stuart
    Seattle Biomedical Research Institute, Seattle, Washington, USA
    J Clin Invest 118:1301-10. 2008
    ....
  68. ncbi Molecular mechanisms of antimony resistance in Leishmania
    Shyam Sundar
    Division of Biochemistry, Central Drug Research Institute, Lucknow 226001, UP India
    J Med Microbiol 56:143-53. 2007
    ..Unravelling the molecular mechanisms of clinical resistance could allow the prevention and circumvention of resistance, as well as rational drug design for the treatment of drug-resistant Leishmania...
  69. ncbi Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic
    S Sundar
    The Kala Azar Medical Research Center, Banaras Hindu University Institute of Medical Sciences, Varanasi, India
    Clin Infect Dis 31:1104-7. 2000
    ..Sb induced long-term cure in 35% (95% confidence interval [CI], 28%-42%) of those in Bihar versus 86% (95% CI, 79%-93%) of those in Uttar Pradesh. In Bihar, the center of the Indian epidemic, traditional Sb treatment should be abandoned...
  70. ncbi A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death
    Baptiste Vergnes
    Centre de Recherche en Infectiologie du Centre de Recherche du CHUL and Division de Microbiologie, Faculte de Medecine, Universite Laval, Quebec G1V 4G2, Canada
    Mol Cell Proteomics 6:88-101. 2007
    ..1 promoted antimonial-induced PCD but protected against miltefosine-induced PCD. This study highlights the important role of PCD in drug susceptibility/resistance in the protozoan parasite Leishmania...
  71. pmc Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial
    Paulo R Machado
    Servico de Imunologia, Hospital Universitario Prof Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil
    PLoS Negl Trop Dis 4:e912. 2010
    ..Cutaneous leishmaniasis (CL) is treated with parenteral drugs for decades with decreasing rate cures. Miltefosine is an oral medication with anti-leishmania activity and may increase the cure rates and improve compliance...
  72. ncbi How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness
    Dieudonné Mumba Ngoyi
    Department of Parasitology, Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo
    J Infect Dis 201:453-63. 2010
    ..CONCLUSION. Combining criteria for failure and cure allows follow-up of patients with second-stage human African trypanosomiasis to be shortened to a maximum duration of 12 months...
  73. ncbi Resistance to antimony and treatment failure in human Leishmania (Viannia) infection
    Ricardo Rojas
    Centro Internacional de Entrenamiento e Investigaciones Medicas, Cali, Colombia, and Centre Hospitalier Universitaire Laval, Quebec, Canada
    J Infect Dis 193:1375-83. 2006
    ..In this study, we sought to determine whether standard treatment selects for resistant organisms and whether drug resistance contributes to treatment failure...
  74. pmc In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences
    Marieke Vermeersch
    Laboratory for Microbiology, Parasitology, and Hygiene LMPH, Faculty of Pharmaceutical, Biomedical, and Veterinary Sciences, University of Antwerp, Groenenborgerlaan 171, 2020 Antwerp, Belgium
    Antimicrob Agents Chemother 53:3855-9. 2009
    ..Axenic systems can be recommended only for compounds for which no cellular mechanisms are involved, for example, amphotericin B and miltefosine...
  75. ncbi Leishmaniasis: current treatment and prospects for new drugs and vaccines
    Lukasz Kedzierski
    Infection and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Pde, Parkville 3050, Victoria, Australia
    Curr Med Chem 16:599-614. 2009
    ....
  76. ncbi Reporter genes facilitating discovery of drugs targeting protozoan parasites
    Anuradha Dube
    Division of Parasitology, Central Drug Research Institute, Lucknow 226 001, India
    Trends Parasitol 25:432-9. 2009
    ....
  77. ncbi Rapid fluorescent assay for screening drugs on Leishmania amastigotes
    Orly Shimony
    The Kuvin Centre for the Study of Infectious and Tropical Diseases, Hebrew University Hadassah Medical School, P O Box 12272, Jerusalem 91220, Israel
    J Microbiol Methods 75:196-200. 2008
    ..This assay only requires a limited number of axenic amastigotes (50,000 cells/well) and can be used to rapidly screen large chemical or natural product libraries for activity against amastigotes...
  78. ncbi Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004
    Piero L Olliaro
    UNICEF UNDP World Bank WHO Special Programme on Research and Training in Tropical Diseases, WHO, Geneva, Switzerland
    Lancet Infect Dis 5:763-74. 2005
    ..India, Bangladesh, and Nepal agreed recently to undertake measures towards the elimination of visceral leishmaniasis. The lessons learnt in Bihar could help inform policy decisions both regionally and elsewhere...
  79. pmc In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity
    Dhiraj Kumar
    Institute of Pathology, Safdarjung Hospital Campus, New Delhi, India
    Antimicrob Agents Chemother 53:835-8. 2009
    ..The results of gene expression analysis of LdMT and LdRos3 were suggestive of alternate mechanisms of Miltefosine susceptibility in the isolates...
  80. ncbi Advances and perspectives in Leishmania cell based drug-screening procedures
    D Sereno
    IRD, UR008 Pathogénie des Trypanosomatidés, 911 Avenue Agropolis, BP 64501, 34394 Montpellier Cedex 5, France
    Parasitol Int 56:3-7. 2007
    ....
  81. ncbi Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo
    Karin Seifert
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Int J Antimicrob Agents 30:229-35. 2007
    ..90% inhibition in wild-type infections). No cross-resistance to other antileishmanial drugs was observed in M-mutR amastigotes...
  82. ncbi Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient
    Basu Dev Pandey
    Sukraraj Tropical and Infectious Diseases Hospital, Kathmandu, Nepal
    Am J Trop Med Hyg 80:580-2. 2009
    ..The patient was subsequently treated with 1 mg/kg of amphotericin B for a total of 14 days and recovered completely...
  83. ncbi Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam
    Yao Zhou
    Department of Biochemistry and Molecular Biology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Biol Chem 279:37445-51. 2004
    ..We propose that LmACR2 is responsible for reduction of the pentavalent antimony in Pentostam to the active trivalent form of the drug in Leishmania...
  84. ncbi Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine)
    Karin Seifert
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Int J Antimicrob Agents 22:380-7. 2003
    ..Resistance was stable up to 12 weeks in drug-free culture medium. No amplification of specific genes, including the multidrug resistance P-glycoprotein gene, could be detected in the resistant parasites...
  85. ncbi Leishmania antimony resistance: what we know what we can learn from the field
    Khatima Ait-Oudhia
    Ecole Nationale Supérieure Vétérinaire d Alger, BP 161, Hassan Badi El Harrach, Alger, Algeria
    Parasitol Res 109:1225-32. 2011
    ..In this review, we discuss on the factors potentially involved in the selection of antimony resistance in the field and discuss on the methods available for its diagnosis...
  86. ncbi Crucial role of cytosolic tryparedoxin peroxidase in Leishmania donovani survival, drug response and virulence
    Jitesh P Iyer
    National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, India
    Mol Microbiol 68:372-91. 2008
    ..Therefore, this study provides a link between cTXNPx expression to survival, virulence and drug response in L. donovani...
  87. ncbi LQB-118, an orally active pterocarpanquinone, induces selective oxidative stress and apoptosis in Leishmania amazonensis
    Grazielle Alves Ribeiro
    Laboratório de Bioquímica de Tripanosomatideos, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil
    J Antimicrob Chemother 68:789-99. 2013
    ..The pterocarpanquinone LQB-118, previously demonstrated to be effective in vivo via oral delivery, was investigated for its mechanism in selective parasite killing...
  88. ncbi Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis
    Masoud Soheilian
    Ocular Inflammatory and Uveitis Service, Department of Ophthalmology, and Ophthalmic Research Center, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    Ophthalmology 112:1876-82. 2005
    ..To compare the efficacy of the classic treatment of ocular toxoplasmosis (pyrimethamine, sulfadiazine, and prednisolone) with a regimen consisting of trimethoprim/sulfamethoxazole (co-trimoxazole) plus prednisolone...
  89. ncbi Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination
    Emilio M Dodds
    Consultores Oftalmologicos, Buenos Aires, Argentina
    Am J Ophthalmol 146:856-65.e2. 2008
    ....
  90. ncbi Anti-malarial, anti-trypanosomal, and anti-leishmanial activities of jacaranone isolated from Pentacalia desiderabilis (Vell.) Cuatrec. (Asteraceae)
    Thiago R Morais
    Centro de Ciências e Humanidades e Centro de Ciências Biológias e da Saúde, Universidade Presbiteriana Mackenzie, 01302 907, Sao Paulo, SP, Brazil
    Parasitol Res 110:95-101. 2012
    ..75 μg/mL) and a selectivity index of 3. The obtained results suggested that jacaranone, as other similar secondary metabolites or synthetic analogs, might be useful tolls for drug design for in vivo studies against protozoan diseases...
  91. ncbi Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection
    Workagegnehu Hailu
    Gondar University Hospital, Gondar, Ethiopia
    Trans R Soc Trop Med Hyg 104:706-12. 2010
    ..These data show that Glucantime can be as effective as Pentostam or SSG in HIV-negative patients. The data also point to clinical pancreatitis as a safety concern, especially in patients with HIV co-infection...
  92. ncbi In vitro and in vivo leishmanicidal activity of Dysoxylum binectariferum and its fractions against Leishmania donovani
    V Lakshmi
    Division of Medicinal and Process Chemistry, Central Drug Research Institute, Lucknow 226 001, India
    Phytomedicine 14:36-42. 2007
    ..o., respectively. The pure compound, rohitukine, obtained from chloroform fraction showed weaker in vitro activity and was ineffective in infected hamsters. The lead potential of this plant need further investigations...
  93. pmc Treatment of Mediterranean visceral leishmaniasis
    L Gradoni
    Laboratorio di Parassitologia, , Rome, Italy
    Bull World Health Organ 73:191-7. 1995
    ....
  94. ncbi A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan
    H Veeken
    Medecins Sans Frontieres Holland, Amsterdam, The Netherlands
    Trop Med Int Health 5:312-7. 2000
    ....
  95. ncbi Antiprotozoal steroidal saponins from the marine sponge Pandaros acanthifolium
    Erik L Regalado
    Department of Chemistry, Center of Marine Bioproducts CEBIMAR, Loma y 37 Alturas del Vedado, C P 10400 Havana, Cuba
    J Nat Prod 73:1404-10. 2010
    ..78 and 0.038 microM, respectively) and Leishmania donovani (IC(50)'s 1.3 and 0.051 microM, respectively)...
  96. pmc Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
    Tansy Edwards
    MRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, UK
    Trials 12:66. 2011
    ..AmBisome® is an efficacious, safe anti-leishmanial treatment. There is growing interest in its use, either as a single dose or in combination treatments. In East Africa, the minimum optimal single-dosage has not been identified...
  97. ncbi Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study
    S Sundar
    Kala azar Medical Research Center, Banaras Hindu University, Varanasi, 221 005, India
    Clin Infect Dis 37:800-4. 2003
    ..Very few adverse events (fever with rigor, in 9.8% of patients) were seen. Single-dose L-AmB (7.5 mg/kg) treatment is safe and effective, and it may be used for the mass treatment of VL in India...
  98. ncbi Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL)
    A M Musa
    Department of Clinical Pathology and Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
    Ann Trop Med Parasitol 99:563-9. 2005
    ..Once certain favourable clinical signs (the regression and/or darkening of the PKDL lesions) have been noted, the lesions will probably continue to clear without the need for more injections...
  99. ncbi Limonoid orthoacetates and antiprotozoal compounds from the roots of Pseudocedrela kotschyi
    Anne Emmanuelle Hay
    Laboratory of Pharmacognosy and Phytochemistry, Geneva Lausanne School of Pharmacy, University of Geneva, CH 1211 Geneva 4, Switzerland
    J Nat Prod 70:9-13. 2007
    ..The crude extract and the two gedunin derivatives exhibited good in vitro activity against all of these parasites...
  100. ncbi Effects of (-) mammea A/BB isolated from Calophyllum brasiliense leaves and derivatives on mitochondrial membrane of Leishmania amazonensis
    M A Brenzan
    Pós doutoranda em Ciências Farmacêuticas, Departamento de Farmácia e Farmacologia, Universidade Estadual de Maringa, Av Colombo 5790, 87020 900 Maringa, PR, Brazil
    Phytomedicine 19:223-30. 2012
    ..In addition, the compound (3) may be acting to depolarize the mitochondrial membrane potential of the cells, leading to death of the parasite...
  101. ncbi Treatment of Bolivian mucosal leishmaniasis with miltefosine
    J Soto
    Consorcio de Investigaciones Bioclinicas, Bogota, Colombia
    Clin Infect Dis 44:350-6. 2007
    ..Although mucosal leishmaniasis is a prominent disease, it has been studied only to a limited extent. It is classically treated with parenteral antimony or, as a last resort, amphotericin B...

Research Grants65

  1. Development of Small Molecules as Antiprotozoal Agents
    Shuren Zhu; Fiscal Year: 2013
    ..The project involves standard approaches to drug development, but the multidisciplinary team and multi- institution collaboration that has been assembled will accelerate the generation of clinical candidates. ..
  2. STRUCTURE SELECTIVITY RELATIONSHIPS OF ANTIBACTERIAL AGE
    CYNTHIA SELASSIE; Fiscal Year: 1992
    ..analysis and molecular graphics in the search for more effective and selective antibacterial and antiprotozoal agents, specifically antifolates...
  3. HOST IMMUNOREGULATION OF ANTILEISHMANIAL CHEMOTHERAPY
    Henry Murray; Fiscal Year: 2005
    ..And Aim 3: Characterize immunostimulation in AmB's efficacy, and in recrudescent infection following AmB therapy, pinpoint the likely cytokine-driven T cell mechanism which prevents post-treatment relapse. ..
  4. Host Immunoregulation of Response to Antileishmanial Chemotherapy
    Henry Murray; Fiscal Year: 2007
    ..abstract_text> ..
  5. Domoic Acid and Neonatal Microglia Activation
    Alejandro Mayer; Fiscal Year: 2004
    ..activated microglia cells and their mediators play in DOM-induced excitotoxic neuronal injury and thus contribute to potential novel approaches for the therapy of the neuropathology associated with Amnesic Shellfish Poisoning in humans ..
  6. Simple, Selective Antimitotic Antiparasitic Agents
    Karl Werbovetz; Fiscal Year: 2007
    ..abstract_text> ..
  7. Host Protein Degradation by Schistosome Parasites
    James McKerrow; Fiscal Year: 2007
    ..abstract_text> ..
  8. Targeting Cysteine Proteases: Antiparasitic Chemotherapy
    James McKerrow; Fiscal Year: 2008
    ..No Abstract Provided. ..
  9. High Throughput Assay for Screening Compounds(RMI)
    James McKerrow; Fiscal Year: 2005
    ..Computational and informatics capability is in place to acquire, store and cross-reference this data, and provide access to the scientific community through an open-source website. ..
  10. TREATMENT OF CONGENITAL TOXOPLASMOSIS
    Rima L McLeod; Fiscal Year: 2010
    ..These studies will contribute to determining how to best provide medical care to children and young adults afflicted with congenital toxoplasmosis and to better understanding pathogenesis of this disease. ..
  11. NOVEL APICOMPLEXAN METABOLISM AND ORGANELLE TRANSIT
    Rima McLeod; Fiscal Year: 2005
    ..gondii, its gene regulation, organelle targeting and better characterization of possible novel antimicrobial agent targets in the shikimate pathway and its branches. ..
  12. International Leptospirosis Society Meeting 2007
    Joseph Vinetz; Fiscal Year: 2007
    ..unreadable] Outcome of the meeting will be assessed by peer-reviewed publication and trainee publication and[unreadable] career advancement. ..
  13. Tinidazole for the Treatment of Bacterial Vaginosis
    Jane Schwebke; Fiscal Year: 2007
    ..In addition, we will measure vaginal and serum concentrations of drug during treatment and correlate with cure rates, short-term recurrence of BV, and severity of infection. ..
  14. Microarray Analysis of Leptospiral Genomes
    Joseph Vinetz; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  15. MOLECULAR TARGETS OF BLOCKING MALARIA TRANSMISSION
    Joseph Vinetz; Fiscal Year: 2005
    ....
  16. NO& Epithelial Repair in Cryptosporidiosis
    Jody Gookin; Fiscal Year: 2006
    ..abstract_text> ..
  17. Role of iNOS and CAT-2 in defense against CP infection
    Jody Gookin; Fiscal Year: 2006
    ..parvum infection. The PI is presently in the 3rd year of a 5-year K08 from NIDDK. These studies are anticipated to generate key preliminary data for the PI's first R01 application ..
  18. Control of Trichomoniasis -A Paradigm for STD Control
    Jane Schwebke; Fiscal Year: 2006
    ..vaginalis, to examine strain differences using PFGE, and to examine the prevalence of resistance strains and their potential contribution to treatment failure. ..
  19. Toxoplasma Adenosine Kinase & Chemotherapy
    MAHMOUD EL KOUNI; Fiscal Year: 2007
    ..Determine the mechanism of selective toxicity of active compounds. These studies will utilize the complementary strengths of the investigators in a collaborative, integrated effort to achieve these goals. [unreadable] [unreadable]..
  20. Therapy and Prevention for Bacterial Vaginosis
    Jane Schwebke; Fiscal Year: 2006
    ..We will also utilize specimens from these prospective studies to further study the association of Mobiluncus, an organism strongly associated with BV using sensitive PCR technology. ..
  21. Inhibition of Alzheimer's Beta-Amyloid Fibril Formation
    Duy Hua; Fiscal Year: 2009
    ..However, soluble oligomeric Abeta showed high neuronal toxicity. Inhibition of the formation of these toxic soluble Abeta oligomers would provide therapeutics for AD. ..
  22. Human Reservoirs of Plasmodium vivax Transmission in the Peruvian Amazon
    Joseph M Vinetz; Fiscal Year: 2010
    ..vivax, and provide a rational basis for determining strategies to implement and deploy new transmission- blocking vaccines as one approach towards the future elimination of P. vivax malaria from the Amazon basin. ..
  23. Leptospirosis Transmission in the Peruvian Amazon
    Joseph Vinetz; Fiscal Year: 2006
    ....
  24. Enhancement of 5-Fluorouracil Chemotherapeutic Efficacy
    MAHMOUD EL KOUNI; Fiscal Year: 2002
    ..This will increase the use of FUra and enhance its commercial potential. Two patents have been awarded to protect the technology and were licensed to the Company. ..
  25. IMMUNODOMINANT TARGETS OF CMI TO CRYPTOSPORIDIUM
    Jan Mead; Fiscal Year: 2009
    ..This will be accomplished by immunizing mice with a DNA construct of these antigens, assessing their ability to elicit immune responses, and challenging mice with C. parvum to determine the degree of protection achieved. ..
  26. Ophthalmic Antibiotic Resistance Study
    Kirk Wilhelmus; Fiscal Year: 2003
    ..abstract_text> ..
  27. ADENOSINE KINASE TARGET FOR CHEMOTHERAPY IN TGONDII
    MAHMOUD EL KOUNI; Fiscal Year: 2001
    ..gondii; (3) evaluate active compounds as potential antitoxoplasmosis agents in vitro and in vivo. ..
  28. Genetics of Innate Immunity in Human Leptospirosis in Brazil
    Joseph Vinetz; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  29. Concordance Rates of Mobiluncus Among Sexual Partners
    Jane Schwebke; Fiscal Year: 2004
    ..Our hypothesis is that Mobiluncus curtisii is important in the pathogenesis of BV and high concordance rates among sexual partners will be found suggesting sexual transmission. ..
  30. MOLECULAR TARGETS OF BLOCKING MALARIA TRANSMISSION
    Joseph M Vinetz; Fiscal Year: 2010
    ..falciparum chitinase, PfCHTI, and provide the scientific basis for developing novel potential approaches to interrupting malaria transmission at the vertebrate host-mosquito vector interface. ..
  31. A Therapeutic Target for Microsporidiosis
    Louis Weiss; Fiscal Year: 2007
    ..In addition, the approaches and methods developed in this R21 should also prove useful for studies on methionine aminopeptidases as therapeutic targets in other pathogenic protists. [unreadable] [unreadable] [unreadable]..
  32. Inhibitors of Hedgehog Signaling For Brain Cancer Chemotherapy
    JEFFREY D contact WINKLER; Fiscal Year: 2010
    ..The studies outlined herein therefore hold the promise of developing important new tools in cancer biology and new drug candidates for the treatment of brain cancers. ..
  33. ANTIAIDS AGENTS FROM MARINE ORGANISMS
    Mark Hamann; Fiscal Year: 2007
    ....
  34. Second International Workshop on Microsporidia from Vertebrate and Invertebrate H
    Louis Weiss; Fiscal Year: 2007
    ..Overall, the goal of this[unreadable] congress is to foster the exchange of information between these diverse groups of[unreadable] scientists leading to advances in research on these emergent pathogens. ..
  35. Plasmodium Falciparum Metal Metabolism
    David Sullivan; Fiscal Year: 2009
    ..Plasmodium parasitism provides a comparison of "simple" erythrocyte cell to more complex infected cell. ..
  36. MOUSE MODELS OF INTESTINAL INFECTION AND INFLAMMATION
    Lars Eckmann; Fiscal Year: 2008
    ..abstract_text> ..
  37. SERINE PROTEINASES IN APICOMPLEXAN PARASITES
    Kami Kim; Fiscal Year: 2009
    ..In addition to illuminating the function and biology of T. gondii secretory organelles, these studies will determine whether subtilases are a viable chemotherapeutic target for treatment of human infections with Apicomplexan parasites. ..
  38. Improved Macaque Safety Model for Topical Microbicides: Post-coital Assessments
    Dorothy Patton; Fiscal Year: 2008
    ..In addition, we will collect parallel assessments, when mating has occurred with a placebo gel (HEC universal placebo) in place. These studies will provide urgently needed data regarding topical microbicide use with coital activity. ..
  39. New Topical Therapies for Psoriasis
    Mitchell Avery; Fiscal Year: 2007
    ..The goal of this project is to develop a safe and effective new drug for topical treatment of psoriasis. [unreadable] [unreadable] [unreadable]..
  40. Vinylogous Amide Photochemistry in Organic Synthesis
    Jeffrey Winkler; Fiscal Year: 2005
    ..abstract_text> ..
  41. Targeted antigen delivery for cancer immunotherapy
    Shoshana Frankenburg; Fiscal Year: 2007
    ..one could treat a much larger number of patients, with the potential to clinically evaluate new antigens and immunotherapeutic modalities, improving the life quality and expectancy of metastatic melanoma patients [unreadable] [unreadable]..
  42. Sterol Biosynthesis in Trypanosomatid Parasites
    Frederick Buckner; Fiscal Year: 2004
    ..The drugs discovered in this research program will hopefully provide better future treatment for patients with these devastating diseases. ..
  43. Generation of Reagents for E. bieneusi Genome Sequencing
    Saul Tzipori; Fiscal Year: 2003
    ..The outcome of this proposal will lead to a submission of a full proposal to sequence the EB genome. ..
  44. Microsporidiosis:A Therapeutic Target
    Louis Weiss; Fiscal Year: 2003
    ....
  45. 7th International Congress on Toxoplasmosis
    Kami Kim; Fiscal Year: 2003
    ..This meeting has fostered an environment of cooperation and collaboration in work on T. gondii that is not seen in other parasitology disciplines and has facilitated rapid and sustained progress in research on this pathogen. ..
  46. APPROACHES TO CHARACTERIZATION OF ANTIINFECTIVE AGENTS
    Mark Hamann; Fiscal Year: 2002
    ..SAR studies will be conducted utilizing chemical and microbial transformations of biologically active secondary metabolites combined with molecular modeling studies. ..
  47. IMMUNITY TO CRYPTOSPORIDIOSIS IN SIV INFECTED MACAQUES
    Saul Tzipori; Fiscal Year: 2002
    ..An understanding of this mechanism is important for the derivation of immunotherapeutic strategies that may be necessary to control chronic cryptosporidiosis in patients with AIDS. ..
  48. STRUCTURAL STUDIES OF THE BACTERIORHODOPSIN PHOTOCYCLE
    Hartmut Luecke; Fiscal Year: 2002
    ....
  49. CRYPTOSPORIDIUM PARVUM GENOME SEQUENCING PROJECT (MINN)
    Mitchell Abrahamsen; Fiscal Year: 2002
    ..parvum genome. ..
  50. PIG MODEL FOR E BIENEUSI
    Saul Tzipori; Fiscal Year: 2002
    ..Given the cost and nature of the simian SIV model it is unlikely this model would serve the same function. ..
  51. TOXOPLASMA DEVELOPMENT AND CELL CYCLE
    Kami Kim; Fiscal Year: 2002
    ..These will be the initial experiments in a long-term effort to define the role of cell cycle regulation in Toxoplasma tachyzoite-bradyzoite differentiation and virulence. ..
  52. Anti-Trypanosomal Agents from a Neotropical Cloudforest
    WILLIAM SETZER; Fiscal Year: 2004
    ..The long-term benefit of this research project is the development of new medicines to treat patients with Chagas disease. ..
  53. POLYAMINE METABOLISM OF CRYPTOSPORIDIA:RATIONAL THERAPY
    Nigel Yarlett; Fiscal Year: 2004
    ..We propose to extend these studies to examine the structural requirements of the polyamine analogues that will result in the most effective inhibition of SSAT activity. ..
  54. RECOMBINANT SHIGA-TOXIN-SPECIFIC HUMAN ANTIBODIES
    Saul Tzipori; Fiscal Year: 2004
    ..abstract_text> ..
  55. Rapid Diagnostics for Category B Enteropathogens
    William Petri; Fiscal Year: 2007
    ..Successful completion of these studies will yield high throughput diagnostic tests that target multiple enteropathogens simultaneously in a single sample. ..
  56. Studies on Cryptosporidium parvum Type 1
    Saul Tzipori; Fiscal Year: 2006
    ..The third aim investigates the extent of genetic variation and exchange within and between the two types of C. parvum to determine whether they belong to one or two species. ..
  57. Purine salvage as a chemotherapeutic target in malaria
    Kami Kim; Fiscal Year: 2002
    ..Inhibitors designed in the Schramm and Grubmeyer laboratories will be tested against P. falciparum cultured in human erythrocytes and in mice infected with P. yoelii, a lethal form of mouse malaria. ..
  58. Dev & Testing of New Medications for Treatment of Emerging Infectious Diseases
    Mitchell Avery; Fiscal Year: 2006
    ..This allows LADDS infrastructure to inch forward now to the last stages of drug development that are achievable with academic economics. [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  59. The mechanism of signal transduction in photoreceptors
    Hartmut Luecke; Fiscal Year: 2006
    ..5. Determine the crystal structure of the primary Anabaena photoreceptor in the ground and signaling state. 6. Determine the structure of the complex of the Anabaena photoreceptor with its putative transducer. [unreadable] [unreadable]..
  60. HOST DEFENSES AGAINST PATHOGENIC E. coli
    Lars Eckmann; Fiscal Year: 2007
    ..coli, thus providing an important basis for designing immunization strategies against these pathogens. ..
  61. Prevention of Catheter-Associated Blood Stream Infections
    David Warren; Fiscal Year: 2007
    ..I will build on the experience outlined in this proposal to establish myself an independent investigator in healthcare epidemiology, studying nosocomial infections and developing interventions to prevent them. [unreadable] [unreadable]..
  62. A screen for small molecule inhibitors of soluble Abeta oligomer assembly
    Harry LeVine; Fiscal Year: 2007
    ..Anti-oligomer compounds could potentially block the cognitive impairment symptoms that oligomers elicit in animal models and interfere with the progression of Alzheimer's disease. [unreadable] [unreadable] [unreadable]..
  63. Comparison of US and European Babesia divergens Isolates
    Patricia Holman; Fiscal Year: 2004
    ..The molecular aspects may provide information that will be useful in future efforts to devise diagnostic tests. ..
  64. Topical Antibiotics to Prevent Lyme Disease
    Gary Wormser; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  65. Outcomes in congenital toxoplasmic retinochoroiditis
    Ruth Gilbert; Fiscal Year: 2005
    ..abstract_text> ..